| Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison K Maman, S Aballea, J Nazir, K Desroziers, ME Neine, E Siddiqui, ... European urology 65 (4), 755-765, 2014 | 324 | 2014 |
| Rate, degree, and predictors of recovery from disability following ischemic stroke GJ Hankey, J Spiesser, Z Hakimi, G Bego, P Carita, S Gabriel Neurology 68 (19), 1583-1587, 2007 | 266 | 2007 |
| Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis C Kelleher, Z Hakimi, R Zur, E Siddiqui, K Maman, S Aballéa, J Nazir, ... European urology 74 (3), 324-333, 2018 | 220 | 2018 |
| Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice CR Chapple, J Nazir, Z Hakimi, S Bowditch, F Fatoye, F Guelfucci, ... European urology 72 (3), 389-399, 2017 | 218 | 2017 |
| Chronic insomnia, quality-of-life, and utility scores: comparison with good sleepers in a cross-sectional international survey D Léger, CM Morin, M Uchiyama, Z Hakimi, S Cure, JK Walsh Sleep medicine 13 (1), 43-51, 2012 | 162 | 2012 |
| Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review G Yeowell, P Smith, J Nazir, Z Hakimi, E Siddiqui, F Fatoye BMJ open 8 (11), e021889, 2018 | 118 | 2018 |
| Qualitative exploration of the patient experience of underactive bladder AD Uren, N Cotterill, C Harding, C Hillary, C Chapple, M Klaver, ... European urology 72 (3), 402-407, 2017 | 85 | 2017 |
| Time frame and predictors of recovery from disability following recurrent ischemic stroke GJ Hankey, J Spiesser, Z Hakimi, P Carita, S Gabriel Neurology 68 (3), 202-205, 2007 | 72 | 2007 |
| Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder SM Notte, TS Marshall, M Lee, Z Hakimi, I Odeyemi, WH Chen, ... BMC urology 12, 1-8, 2012 | 60 | 2012 |
| Mirabegron as add-on treatment to solifenacin in patients with incontinent overactive bladder and an inadequate response to solifenacin monotherapy S MacDiarmid, S Al-Shukri, J Barkin, A Fianu-Jonasson, P Grise, ... The Journal of Urology 196 (3), 809-818, 2016 | 57 | 2016 |
| Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting Z Hakimi, S Aballéa, S Ferchichi, M Scharn, IA Odeyemi, M Toumi, ... Transplant Infectious Disease 19 (5), e12732, 2017 | 49 | 2017 |
| Patient‐reported outcomes from SYNERGY, a randomized, double‐blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and … D Robinson, C Kelleher, D Staskin, ER Mueller, C Falconer, J Wang, ... Neurourology and Urodynamics 37 (1), 394-406, 2018 | 45 | 2018 |
| Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms CR Chapple, MJ Drake, P Van Kerrebroeck, L Cardozo, T Drogendijk, ... BJU international 113 (5), 696-703, 2014 | 45 | 2014 |
| Cost-effectiveness of mirabegron compared with antimuscarinic agents for the treatment of adults with overactive bladder in the United Kingdom J Nazir, K Maman, ME Neine, B Briquet, IAO Odeyemi, Z Hakimi, ... Value in Health 18 (6), 783-790, 2015 | 34 | 2015 |
| Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom S Aballéa, K Maman, K Thokagevistk, J Nazir, IAO Odeyemi, Z Hakimi, ... Clinical Drug Investigation 35, 83-93, 2015 | 33 | 2015 |
| Patient‐reported outcomes with the β3‐adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder V Khullar, G Amarenco, JC Angulo, MB Blauwet, J Nazir, IA Odeyemi, ... Neurourology and Urodynamics 35 (8), 987-994, 2016 | 31 | 2016 |
| Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder K Desroziers, S Aballéa, K Maman, J Nazir, I Odeyemi, Z Hakimi Health and Quality of Life Outcomes 11, 1-9, 2013 | 28 | 2013 |
| Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a … Z Hakimi, M Johnson, J Nazir, B Blak, IAO Odeyemi Current medical research and opinion 31 (1), 43-50, 2015 | 27 | 2015 |
| The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from … D Castro-Diaz, CR Chapple, Z Hakimi, MB Blauwet, L Delgado-Herrera, ... Quality of Life Research 24, 1719-1727, 2015 | 26 | 2015 |
| Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta … J Nazir, C Kelleher, S Aballea, K Maman, Z Hakimi, C Mankowski, ... Neurourology and Urodynamics 37 (3), 986-996, 2018 | 24 | 2018 |
